AARDVARK BIOTECH LIMITED ABBREVIATED ACCOUNTS FOR THE YEAR ENDED 31ST JANUARY 2012

FRIDAY



LD2 29/06/2012 COMPANIES HOUSE

#8

Company Registration Number 03502208

AARDVARK BIOTECH LIMITED

ABBREVIATED BALANCE SHEET 31st JANUARY 2012

TANGIBLE FIXED ASSETS (Note 2)	<u>2012</u> 1	<u>2011</u> 1
CURRENT ASSETS Cash at Bank and in hand	154	154
CREDITORS: Amounts falling due within one year		_ _ =
NET CURRENT ASSETS	<u>154</u>	<u>154</u>
TOTAL ASSETS	£ 155	£ 155

CAPITAL AND RESERVES Called-up equity share capital (Note 3) Profit and Loss Account	100 <u>55</u>	100 _55
SHAREHOLDERS FUNDS	£ 155	£ 155

The directors are satisfied that the company is entitled to exemption from the provisions of the Companies Act 2006 (the Act) relating to the audit of the accounts for the year by virtue of section 480 and that no member or members have requested an audit pursuant to section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the provisions for companies subject to the small companies regime.

These financial statements were approved by the directors on the 27th February 2012 and are signed on their behalf by:

5 Davey

Dr S. N DAVEY

AARDVARK BIOTECH LIMITED

NOTES TO THE ABBREVIATED ACCOUNTS YEAR ENDED 31ST JANUARY 2012

1 ACCOUNTING POLICIES

(a) Basis of accounting

The financial statements have been prepared under the historical cost Convention, and in accordance with the provisions for companies subject to the small companies regime

2 TANGIBLE FIXED ASSETS

	COST		<u>Equipment</u>
	COST At 1 st February 2011 and 31 st January 2012		£ 1659
	DEPRECIATION At 1 st February 2011 and		
	31 st January 2012		£ 1658
	NET BOOK VALUE		
	At 31 st January 2012 (At 31 st January 2011 £1)		£ 1
3	SHARE CAPITAL Authorised share capital:		
	100 Ordinary shares of £1 each	100	100
	Allotted, called up and fully paid:	-	
	Ordinary share capital	100	100

4 RELATED PARTY TRANSACTIONS

The company was under the control of Dr. S. N. Davey throughout the current year and previous period. Dr. S. N. Davey is the managing director and majority shareholder.